AU
CA
NZ
UK
US
IND
Last update at 2025-09-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Wed 27 Nov 24, 12:00 PMTSX Venture Exchange Stock Maintenance Bulletins
Sat 13 Feb 21, 06:25 AM| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Income before tax | -27.75200M | -15.84800M | -5.99500M | -5.29315M | -7.61268M |
| Minority interest | - | - | - | - | - |
| Net income | -26.56000M | -16.70900M | -7.34000M | -4.94743M | -7.61747M |
| Selling general administrative | 19.81M | 16.97M | 12.65M | 7.95M | 7.65M |
| Selling and marketing expenses | 3.61M | 0.74M | 0.69M | 0.38M | 0.82M |
| Gross profit | 11.56M | 10.98M | 11.54M | 8.03M | 5.29M |
| Reconciled depreciation | 6.68M | 3.77M | 3.71M | 3.41M | 2.26M |
| Ebit | -27.94900M | -15.89100M | -3.89400M | -3.77461M | -6.19495M |
| Ebitda | -21.26400M | -12.12200M | -0.18100M | -0.36626M | -3.93166M |
| Depreciation and amortization | 6.68M | 3.77M | 3.71M | 3.41M | 2.26M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -26.09100M | -15.78100M | -6.65300M | -4.09400M | -6.22687M |
| Other operating expenses | 48.88M | 35.53M | 22.09M | 18.10M | 17.15M |
| Interest expense | 0.03M | 0.42M | 0.86M | 1.44M | 1.32M |
| Tax provision | -1.19200M | 0.86M | 1.34M | -0.34573M | 0.00479M |
| Interest income | 0.27M | 0.28M | 0.28M | 0.27M | 0.03M |
| Net interest income | 0.24M | -0.14000M | -0.58100M | -0.26449M | -0.38350M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.19200M | 0.86M | 1.34M | -0.34573M | 0.00479M |
| Total revenue | 20.66M | 19.36M | 17.91M | 14.06M | 10.93M |
| Total operating expenses | 39.78M | 27.15M | 15.71M | 12.08M | 11.52M |
| Cost of revenue | 9.10M | 8.38M | 6.37M | 6.02M | 5.63M |
| Total other income expense net | 0.23M | 0.46M | -1.23800M | -0.08232M | -0.09922M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -26.56000M | -16.70900M | -7.34000M | -4.94743M | -7.61747M |
| Net income applicable to common shares | -26.56000M | -16.70900M | -7.34000M | -4.94743M | -7.61747M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Total assets | 77.81M | 93.49M | 66.96M | 27.26M | 28.35M |
| Intangible assets | 30.93M | 32.39M | 6.06M | 8.29M | 8.42M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.57M | 2.76M | 2.27M | 0.61M | 0.33M |
| Total liab | 20.01M | 18.21M | 10.04M | 12.18M | 10.28M |
| Total stockholder equity | 57.80M | 75.28M | 56.92M | 15.09M | 18.07M |
| Deferred long term liab | 0.02M | 0.03M | 0.03M | 0.11M | - |
| Other current liab | 0.44M | 1.26M | 0.96M | 1.81M | 2.06M |
| Common stock | 117.47M | 114.56M | 80.10M | 34.09M | 32.70M |
| Capital stock | 117.47M | 114.56M | 80.10M | 34.09M | 32.70M |
| Retained earnings | -73.08800M | -46.52800M | -29.81900M | -22.47865M | -17.47648M |
| Other liab | 7.94M | 8.60M | 1.49M | 2.61M | 3.09M |
| Good will | 19.17M | 19.70M | 7.78M | 7.91M | 8.25M |
| Other assets | 0.44M | 0.48M | 0.16M | 0.29M | 0.07M |
| Cash | 8.28M | 29.96M | 41.76M | 2.61M | 5.47M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.92M | 9.26M | 6.07M | 7.93M | 7.20M |
| Current deferred revenue | 0.98M | 1.03M | 1.11M | 1.47M | 0.72M |
| Net debt | -1.01300M | -27.41900M | -38.30200M | 1.90M | -2.54457M |
| Short term debt | 1.12M | 2.20M | 0.99M | 2.87M | 2.83M |
| Short long term debt | - | 1.31M | - | 2.12M | 2.79M |
| Short long term debt total | 7.27M | 2.55M | 3.46M | 4.51M | 2.93M |
| Other stockholder equity | 10.80M | 7.25M | 6.64M | 3.48M | 2.85M |
| Property plant equipment | 10.39M | 3.34M | 4.02M | 3.06M | 1.56M |
| Total current assets | 16.79M | 37.47M | 48.86M | 7.70M | 9.88M |
| Long term investments | 0.12M | 0.14M | 0.11M | 0.12M | 0.09M |
| Net tangible assets | 7.73M | 23.22M | 43.11M | -1.00859M | -0.12195M |
| Short term investments | - | - | - | 0.00010M | - |
| Net receivables | 4.42M | 3.41M | 4.12M | 3.75M | 1.95M |
| Long term debt | - | - | 1.53M | 0.50M | 0.03M |
| Inventory | 2.06M | 1.61M | 1.20M | 0.82M | 2.12M |
| Accounts payable | 3.39M | 4.77M | 3.01M | 1.77M | 1.59M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.62M | -2.47900M | -0.68700M | -0.30022M | -0.22806M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 80.10M | 34.09M | 32.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.09M | 0.08M | 0.08M | 0.09M | 0.07M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 61.02M | 56.02M | 18.10M | 19.56M | 18.47M |
| Capital lease obligations | 7.27M | 1.23M | 1.93M | 1.88M | 0.11M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Investments | -1.96700M | -5.20800M | -2.45600M | -1.58308M | -2.20181M |
| Change to liabilities | -1.74500M | 1.45M | 0.62M | 0.92M | -0.01452M |
| Total cashflows from investing activities | -1.96700M | -5.20800M | -2.45600M | -1.58308M | -2.20181M |
| Net borrowings | -1.33700M | -0.96200M | -0.77200M | -0.31848M | -0.20269M |
| Total cash from financing activities | -0.62100M | 2.88M | 43.38M | 0.17M | 9.35M |
| Change to operating activities | -0.80600M | -0.62000M | -1.34200M | -0.19289M | 0.00893M |
| Net income | -26.56000M | -16.70900M | -7.34000M | -4.94743M | -7.61747M |
| Change in cash | -21.68100M | -11.79100M | 39.15M | -2.84827M | 3.73M |
| Begin period cash flow | 30.05M | 41.84M | 2.69M | 5.54M | 1.81M |
| End period cash flow | 8.37M | 30.05M | 41.84M | 2.69M | 5.54M |
| Total cash from operating activities | -19.83300M | -9.92100M | -0.60000M | -1.39129M | -3.20660M |
| Issuance of capital stock | 0.72M | 3.85M | 44.15M | 0.49M | 9.84M |
| Depreciation | 6.68M | 3.77M | 3.71M | 3.41M | 2.26M |
| Other cashflows from investing activities | 0.04M | -0.25900M | -0.25900M | -0.25900M | -0.25900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.18500M | -0.50100M | -0.31600M | -0.02339M | 0.29M |
| Change to account receivables | -0.56100M | 0.16M | -0.43900M | -0.93328M | 0.10M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -1.96700M | -0.00500M | 2.20M | 0.60M | -0.08850M |
| Change to netincome | 3.32M | 2.44M | 4.04M | 1.27M | 1.57M |
| Capital expenditures | 1.50M | 1.26M | 1.43M | 0.58M | 0.65M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -3.27600M | 0.58M | -1.01800M | -1.11819M | 0.58M |
| Stock based compensation | 1.94M | 3.08M | 2.75M | 0.74M | 1.11M |
| Other non cash items | 2.30M | -0.31000M | 1.38M | 0.98M | 1.03M |
| Free cash flow | -21.32800M | -11.17800M | -2.02700M | -1.96694M | -3.85165M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IPA Immunoprecise Antibodies Ltd |
- -% | 2.07 | - | - | 1.51 | 0.94 | 1.70 | -3.7057 |
| NVO Novo Nordisk A/S |
-1.06 2.66% | 38.72 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 38.88 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
38.30 8.31% | 499.17 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-9.57 1.22% | 772.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
| Name | Title | Year Born |
|---|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | CEO, Pres & Non-Independent Director | NA |
| Mr. Brad McConn | Chief Financial Officer | NA |
| Dr. Ilse Roodink | Chief Scientific Officer | NA |
| Mr. David E. Orton | Chief Operating Officer | NA |
| Ms. Carla Dahl | VP of Marketing | NA |
| Dr. Barry Neil Duplantis | VP of Client Relations | NA |
| Dr. Jennifer Lynne Bath Ph.D. | CEO, President & Non-Independent Director | NA |
| Dr. Ilse Roodink | Chief Scientific Officer & Interim General Manager of IPA Europe, Oss | NA |
| Ms. Kristin Taylor CPA, M.B.A. | Chief Financial Officer | NA |
| Dr. Roland Romijn | Head of General Operations of the Utrecht site of IPA (Europe) | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...